Prediction of Malignant Thyroid Nodules Using 18 F-FDG PET/CT-Based Radiomics Features in Thyroid Incidentalomas

Clin Nucl Med. 2023 Jun 1;48(6):497-504. doi: 10.1097/RLU.0000000000004637. Epub 2023 Mar 29.

Abstract

Objective: The purpose of the current study was to evaluate the diagnostic performances of 18 F-FDG PET/CT-based radiomics features for prediction of malignant thyroid nodules (TNs) in thyroid incidentaloma (TI).

Methods: PubMed, Cochrane database, and EMBASE database, from the earliest available date of indexing through December 31, 2022, were searched for studies evaluating diagnostic performance of 18 F-FDG PET/CT-based radiomics features for prediction of malignant TNs in TI. We determined the sensitivities and specificities across studies, calculated positive and negative likelihood ratios (LRs; positive and negative LRs), and estimated pooled area under the curve.

Results: Across 5 studies (518 patients), the pooled sensitivity of 18 F-FDG PET/CT was 0.77 (95% confidence interval [CI], 0.67-0.84), and a pooled specificity was 0.67. Likelihood ratio syntheses gave an overall positive LR of 2.3 (95% CI, 1.5-3.6) and negative LR of 0.35 (95% CI, 0.26-0.47). The pooled diagnostic odds ratio was 7 (95% CI, 4-12). The pooled area under the curve of fixed effects was 0.763 (95% CI, 0.736-0.791), and that of random effects was 0.763 (95% CI, 0.721-0.805).

Conclusion: 18 F-FDG PET/CT-based radiomics features showed a good diagnostic performance for prediction of malignant TNs in TI.

MeSH terms

  • Fluorodeoxyglucose F18
  • Humans
  • Positron Emission Tomography Computed Tomography*
  • Radiopharmaceuticals
  • Sensitivity and Specificity
  • Thyroid Nodule* / diagnostic imaging

Substances

  • Fluorodeoxyglucose F18
  • Radiopharmaceuticals